Advice

following an abbreviated submission

adalimumab (Humira®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.

SMC restriction: Patients with severe disease as defined by a total Psoriasis Area Severity Index (PASI) score of  ≥10 and a Dermatology Life Quality Index (DLQI) of >10.

Treatment with adalimumab in a paediatric population improves both signs and symptoms of psoriasis and quality of life.

Download detailed advice110KB (PDF)

Download

Medicine details

Medicine name:
adalimumab (Humira)
SMC ID:
1068/15
Indication:
Treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.
Pharmaceutical company
AbbVie Ltd
BNF chapter
Skin
Submission type
Abbreviated
Status
Superseded
Date advice published
13 July 2015
Additional notes

NICE MTA Advice:  SMC Advice is superseded by National Institute for Health and Care Excellence (NICE) Multiple Technology Appraisal (MTA)